Plain-English translation of NCT06096246 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a procedure called pulmonary vein isolation (a type of catheter ablation that targets the source of irregular heartbeats) works better than the traditional approach of using electrical cardioversion (a controlled shock to reset your heart rhythm) for treating persistent atrial fibrillation. Researchers want to find out which approach helps more patients stay in a normal heart rhythm long-term and causes fewer complications.
Currently, doctors often use electrical cardioversion as a first-line treatment for persistent atrial fibrillation, but it has high recurrence rates and serious side effects. This trial exists to see whether performing the ablation procedure first might be a better strategy, since this comparison has never been properly tested in a rigorous clinical study.
You likely qualify if…
You likely don't qualify if…
You will have a small monitoring device (an implantable loop recorder) inserted under your skin at least one week before your procedure. On the day of treatment, you will undergo a cardiac catheterization procedure where thin tubes are inserted through your groin to access your heart. You will then be randomly assigned to receive either electrical cardioversion alone or catheter ablation (pulmonary vein isolation) followed by cardioversion if needed. The study uses blinding where possible, meaning you and some of your care team may not know which treatment you received until after the procedure.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United Kingdom